What changed in this filing

/stocks — the workspaceLOADING

Item 5. Other Information

2023-11-15 compared with 2023-08-14 · 75 added, 68 removed, 90 unchanged (61% of the section changed)

OTHER INFORMATION.

The following exhibits are filed herewith:

Share Exchange Agreement, dated February 8, 2016 (1)

Articles of Incorporation of the Company (2)

Bylaws of the Company (3)

Certificate of Amendment to Articles of Incorporation

filed on March 21, 2016 (4)

Certificate of Amendment to Articles of Incorporation

filed on December 21, 2016 (5)

Certificate of Amendment to Articles of Incorporation

filed on March 30, 2020 (6)

Certificate of Amendment to Articles of Incorporation

filed on February 17, 2021 (29)

Form of Warrant (7)

Form of Investor Warrant dated May 16, 2022 (32)

Collaboration Agreement dated December 29, 2015 (8)

Collaborative Agreement and Milestone Payment Agreement

dated June 9, 2016 (9)

Employment Agreement with Kira Huang (10)

Addendum to the Collaboration Agreement dated January

12, 2017 (11)

Collaboration Agreement with BioFirst dated July 24,

Co-Development Agreement with Rgene dated May 26, 2017

Employment Agreement with Dr.

The following

exhibits are filed herewith:

Exchange Agreement, dated February 8, 2016 (1)

of Incorporation of the Company (2)

of the Company (3)

of Amendment to Articles of Incorporation filed on March 21, 2016 (4)

of Amendment to Articles of Incorporation filed on December 21, 2016 (5)

of Amendment to Articles of Incorporation filed on March 30, 2020 (6)

of Amendment to Articles of Incorporation filed on February 17, 2021 (29)

of Warrant (7)

of Investor Warrant dated May 16, 2022 (32)

Collaboration

Agreement dated December 29, 2015 (8)

Collaborative

Agreement and Milestone Payment Agreement dated June 9, 2016 (9)

Agreement with Kira Huang (10)

to the Collaboration Agreement dated January 12, 2017 (11)

Collaboration

Agreement with BioFirst dated July 24, 2017 (12)

Co-Development

Agreement with Rgene dated May 26, 2017 (13)

Agreement with Dr.

Chi-Hsin Richard King (15)

Employment Agreement with Chihliang An (25)

Business Loan Agreement

entered by and between Cathay Bank and American BriVision (Holding) Corporation (16)

Promissory Note entered by American BriVision (Holding)

Corporation (17)

Form of Commercial Security Agreement (18)

Form of Exchange Agreement entered into by and between

the Company and non-US person (19)

Form of Exchange Agreement entered into by and between the Company and US person (20)

Form of Securities Purchase Agreement entered into

by and between the Company and U.S.

Agreement with Chihliang An (25)

Loan Agreement entered by and between Cathay Bank and American BriVision (Holding) Corporation (16)

Note entered by American BriVision (Holding) Corporation (17)

of Commercial Security Agreement (18)

of Exchange Agreement entered into by and between the Company and non-US person (19)

of Exchange Agreement entered into by and between the Company and US person (20)

of Securities Purchase Agreement entered into by and between the Company and U.S.

investors (21)

Form of Securities Purchase Agreement entered into

by and between the Company and non-U.S.

of Securities Purchase Agreement entered into by and between the Company and non-U.S.

investors (22)

Amended and Restated American BriVision (Holding) Corporation

2016 Equity Incentive (26)

Form of Securities Purchase Agreement (27)

Form of Convertible Promissory Note (27)

Amendment No.

and Restated American BriVision (Holding) Corporation 2016 Equity Incentive (26)

of Securities Purchase Agreement (27)

of Convertible Promissory Note (27)

1 to Promissory Note (28)

Joint Venture Agreement between the Company, Lucidiam

Venture Agreement between the Company, Lucidiam Co., Ltd.

And BioLite Japan K.K.

Amendment to the Collaboration Agreement dated December 29, 2015 (34)

Clinical Development Service

Agreement with Rgene (portions of the exhibit have been omitted because they (i) are not material and (ii) is the type of information

that the registrant treats as private or confidential.)(31)

Promissory Note issued to Regene, dated June 16, 2022 (31)

Form of Securities Purchase Agreement dated May 12,

Securities Purchase Agreement(33)

Form of Note(33)

Form of Warrant(33)

to the Collaboration Agreement dated December 29, 2015 (34)

Development Service Agreement with Rgene (portions of the exhibit have been omitted because they (i) are not material and (ii) is

the type of information that the registrant treats as private or confidential.)(31)

Note issued to Regene, dated June 16, 2022 (31)

of Securities Purchase Agreement dated May 12, 2022 (32)

Purchase Agreement(33)

of Warrant(33)

Agreement(33)

Security Agreement(33)

Guarantor Security Agreement(33)

Trademark Security Agreement with Rgene Corporation(33)

Trademark Security Agreement with BioFirst Corporation(33)

Patent Security Agreement(33)

Stock Pledge Agreement(33)

Certifications pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.+

Certifications pursuant to 18 U.S.C.

Security Agreement with Rgene Corporation(33)

Security Agreement with BioFirst Corporation(33)

Security Agreement(33)

Pledge Agreement(33)

The Cooperation Agreement between the Company and Zhong Hui Lian He Ji Tuan, Ltd.

dated August 14, 2023 (35)

to the Cooperation Agreement (36)

Agreement (37)

License Agreement between the Company and AiBtl BioPharma, Inc+

License Agreement between the BioLite and AiBtl BioPharma, Inc+

Certifications

pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302

of the Sarbanes-Oxley Act of 2002.+

Certifications

pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302

of the Sarbanes-Oxley Act of 2002.+

Certifications

pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*+

Certifications pursuant to 18 U.S.C.

Certifications

pursuant to 18 U.S.C.

Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*+

74 unchanged sentences

to the Company’s Current Report on Form 8-K, filed on February 24, 2023.

Incorporated by reference to the Company’s Current Report on Form 8-K, filed on February 22, 2022.

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Incorporated by reference

to the Company’s Current Report on Form 8-K, filed on February 22, 2022.

Incorporated by reference

to the Company’s Current Report on Form 8-K, filed on August 17, 2023.

Incorporated by reference

to the Company’s Current Report on Form 8-K, filed on September 6, 2023.

Incorporated by reference

to the Company’s Current Report on Form 8-K, filed on September 13, 2023.

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned thereunto duly authorized.

ABVC BioPharma, Inc.

August 14, 2023

/s/ Uttam Patil

November 15, 2023

Chief Executive Officer

1 unchanged sentence

ABVC BioPharma, Inc.

August 14, 2023

/s/ Leeds Chow

November 15, 2023

Chief Financial Officer

1 unchanged sentence

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 5. Other Information